NCE-1 Intelligence & Market Opportunity

Blujepa

Gepotidacin

Antibiotic

Oral Tablet

Blujepa treats uncomplicated urinary tract infections in females and adolescents with more than 12 years and more than or equal to 40 kg. It’s an oral antibiotic in a new class that combats common UTI bacteria and tackles antibiotic resistance.

Approval Date

25-Mar-25

NCE-1 Date

25-Mar-29

NCE Date

25-Mar-30

Commercial snapshot

Market performance & projections

Revenue ($M)

CAGR (%)

Projected sales, 2026–2032 ($M)

Analyst projection, $M per year

2026

2027

173

2028

268

2029

320

2030

364

2031

407

2032

448

Molecule profile

Details & specifications

Molecule

Gepotidacin

Innovator

GLAXOSMITHKLINE LLC

Dosage Form

Oral Tablet

Strength

EQ 750 mg base

Therapeutic Category

Antibiotic

Usage

To treat uncomplicated urinary tract infections

Good to know

Frequently asked questions

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.

Why Spring Bio Solution

Supported 1000+ clinical trials globally

Provides services across regulatory, legal & clinical research

Unmatched intelligence on batches, expiry, spacing, and historical data from innovators

Integrated CRO services as part of our offerings

Insights on global pricing for smarter clinical trial supply decisions

Global sourcing capability across US, EU, South Africa, Canada, Japan, Australia, New Zealand, Southeast Asia, and other key markets